Tandem Diabetes Care (NASDAQ:TNDM) Given New $53.00 Price Target at Barclays
Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its price objective lowered by Barclays from $60.00 to $53.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the medical device company’s stock. Other analysts have also recently issued research reports about the company. Royal Bank of Canada […]
Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its price objective lowered by Barclays from $60.00 to $53.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the medical device company’s stock. Other analysts have also recently issued research reports about the company. Royal Bank of Canada […]
